Perceptive Advisors Lifts Solid Biosciences Stake to 11.2% with $0.001 Pre-Funded Warrants
SLDB has more than doubled off its 52-week low of $3.79.
Summary
Perceptive Advisors disclosed an 11.2% stake in Solid Biosciences, including 8.9 million pre-funded warrants exercisable at $0.001, though a 9.99% ownership cap currently prevents exercise.
Key Events · Ownership and Investor Activity · SLDB
-
Perceptive Stake Rises to 11.2%
Perceptive Advisors and Joseph Edelman report beneficial ownership of 12,046,579 shares, up from prior levels, representing 11.2% of Solid Biosciences' 107.4 million shares outstanding.
-
Pre-Funded Warrants Add Potential Upside
Perceptive Life Sciences Master Fund holds 8,912,655 pre-funded warrants exercisable at $0.001 per share, but a 9.99% beneficial ownership limitation currently blocks any exercise.
-
CIO Options Included in Stake
Adam Stone, Perceptive's CIO, holds 217,433 stock options, of which 139,933 are exercisable within 60 days, contributing to the aggregate ownership.
-
Institutional Conviction Builds
This filing follows RA Capital Management's 13D/A in June showing an 11.9% stake, indicating sustained institutional accumulation in Solid Biosciences.
Analysis · SLDB · Life Sciences
A major life sciences investor, Perceptive Advisors, now controls 11.2% of Solid Biosciences through 11.8 million shares and 8.9 million pre-funded warrants. The warrants are exercisable at $0.001 per share but are currently blocked by a 9.99% beneficial ownership cap, meaning Perceptive cannot convert them without exceeding the limit. This filing reveals a significant accumulation of potential voting power and economic interest, though the actual exercise is constrained. The stake increase follows a period of heavy insider and institutional buying, including RA Capital's 11.9% stake reported in June, suggesting strong conviction in the company's gene therapy pipeline despite recent losses.
At the time of this filing, SLDB was trading at $9.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $986.5M. The 52-week trading range was $3.79 to $11.45. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.